Scalper1 News
Four big drug companies gave mixed fourth-quarter reports and guidance Tuesday as patent losses and foreign-exchange rates clouded the near-term future, while gene-sequencer Illumina posted better-than-expected earnings. After the close, Amgen (AMGN) said its Q4 earnings rose 19% to $2.16 a share, beating consensus by 11 cents. Revenue for the big biotech rose 6% to $5.33 billion, more than $100 million above views. The company affirmed 2015 Scalper1 News
Scalper1 News